- Aust Prescr 2001;24:108-11
- 1 January 2001
- DOI: 10.18773/austprescr.2001.024
Some of the views expressed in the following notes on newly approved products should be regarded as preliminary, as there may have been limited published data at the time of publication, and little experience in Australia of their safety or efficacy. However, the Editorial Executive Committee believes that comments made in good faith at an early stage may still be of value. Before new drugs are prescribed, the Committee believes it is important that more detailed information is obtained from the manufacturer's approved product information, a drug information centre or some other appropriate source.
Femtran 25 and Femtran 75 (3M Pharmaceuticals)
2 mg and 5.7 mg transdermal patches